ConsumerBiotech & Life SciencesHealthcareAISaaSFintechE-Commerce & MarketplaceFood & AgricultureEducationManufacturing
Invus is a global investment firm headquartered in New York with offices in Paris, Hong Kong, and Singapore. Founded in 1985, it operates a continuous capital structure with over $10 billion under management, partnering with entrepreneurs across consumer, technology, and life sciences sectors from early-stage growth through public companies.
47% of their portfolio is in Biotech & Life Sciences. Average disclosed round size is $138.1M (across 172 rounds with reported amounts).
Portfolio
158
Fund Size
—
Top Stage
Series B
Last 12 Mo
13
Team
GP
Gretchen Piller
Managing Director
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
213 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Precision | Series D | $250M | Sep 2026 |
 Agomab Therapeutics | Series D | $89M | Sep 2026 |
 Encoded Therapeutics | Series F | $275M | Sep 2026 |
 Lupin | Series A | — | Sep 2026 |
| LLupin Dental | Series A | — | Sep 2026 |
| LLifeMine | Series E | $188M | Aug 2026 |
 City Therapeutics | Series B | $99.5M | Jun 2026 |
 Oxford Quantum Circuits | Series C | — | Jun 2026 |
| CCorxel Pharmaceuticals Limited | Series D | $287M | Jan 2026 |
 Mirador | Series B | $250M | Jan 2026 |
 Mirador Tx | Series B | $250M | Jan 2026 |
| Encoded Therapeutics | Series F | $275M | Jan 2026 |
 Ripplematch | Series B | $80M | Jan 2026 |
| EEncoded | Series F | $275M | Jan 2026 |
 SanegeneBio | Series B | $110M | Jan 2026 |
 Triana Biomedicines | Series B | $120M | Dec 2025 |
 Artios | Series D | $115M | Nov 2025 |
 Bambusa Therapeutics | Series A | — | Nov 2025 |
| HHemab | Series C | $157M | Oct 2025 |
 Rani Therapeutics | Series C | $60.3M | Oct 2025 |
 VeraDermics | Series C | — | Oct 2025 |
| KKailera | Series B | $600M | Oct 2025 |
 One Biosciences | Series A | — | Jul 2025 |
 Home Biosciences | Series A | — | Jul 2025 |
| Bambusa Therapeutics | Series A | $90M | Feb 2025 |
Page 1 of 9
Top Co-Investors
RA Capital Management38 shared
OrbiMed35 shared
ARCH Venture Partners27 shared
Sofinnova Partners24 shared
Polaris Partners23 shared
Alexandria Venture Investments23 shared
Redmile Group21 shared
GV20 shared
Perceptive Advisors18 shared
Boxer Capital17 shared
Casdin Capital16 shared
Fidelity Investments15 shared
Deep Track Capital15 shared
Samsara BioCapital15 shared
Omega Funds14 shared
Cormorant Asset Management14 shared
Surveyor Capital14 shared
Pfizer Ventures13 shared
T. Rowe Price13 shared
Last updated: 7 October 2026